Guo-Cai Wu
YOU?
Author Swipe
View article: Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study
Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study Open
Background: OB756 is a novel, orally administered, selective JAK2 inhibitor that targets the JAK–STAT signaling pathway. It has been reported to produce significant therapeutic effects with an acceptable safety profile in Janus-kinase-inhi…
View article: Identification and validation of three tumor suppressors associated with the immune response of acute myeloid leukemia
Identification and validation of three tumor suppressors associated with the immune response of acute myeloid leukemia Open
Background Acute myeloid leukemia (AML) is a heterogeneous disorder marked by irregular expansion and maturation, giving rise to the aggregation of immature myeloid precursor cells. Although most patients achieve remission with initial tre…
View article: The m C methyltransferase NSUN2 promotes progression of acute myeloid leukemia by regulating serine metabolism
The m C methyltransferase NSUN2 promotes progression of acute myeloid leukemia by regulating serine metabolism Open
Acute myeloid leukemia (AML) is one of the most prevalent heterogeneous hematologic malignancies with a complicated etiology. RNA post-transcriptional modifications have been linked to the incidence and progression of AML, while the detail…
View article: Exploration of Euscaphic Acid on Non-Hodgkin Lymphoma Based on Network Pharmacology, Molecular Docking and Cell Experiment
Exploration of Euscaphic Acid on Non-Hodgkin Lymphoma Based on Network Pharmacology, Molecular Docking and Cell Experiment Open
Background: Euscaphic acid (EA) has been found that can inhibit the proliferation of various types of tumor cells, including non-Hodgkin's lymphoma (NHL) cells. However, the underlying mechanism of EA in the treatment of NHL is unclear. Ob…
View article: A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study
A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study Open
Introduction ：OB756 is a novel small molecule Janus kinase2（JAK2）inhibitor which inhibits cell proliferation, induces cell apoptosis by affecting JAK-STAT signaling pathway in preclinical studies. Here we investigated the safety and effica…
View article: Validation for the function of protein C in mouse models
Validation for the function of protein C in mouse models Open
Objectives Protein C (PC) is an anticoagulant that is encoded by the PROC gene. Validation for the function of PC was carried out in mouse models. Methods In this study, autosomal recessive PC deficiency (PCD) was selected as the target, a…
View article: Study on the mechanism of Euscaphic acid in the treatment of non-Hodgkin lymphoma based on network pharmacology and molecular docking
Study on the mechanism of Euscaphic acid in the treatment of non-Hodgkin lymphoma based on network pharmacology and molecular docking Open
Non-Hodgkin's lymphoma (NHL) is a highly heterogenous disease. 5-year survival duration after diagnosis is poor among patients with aggressive/relapsing form of NHL. Our previous research found for the first time that Euscaphic acid (EA) h…
View article: Identification and validation of a prognostic risk-scoring model for AML based on m7G-associated gene clustering
Identification and validation of a prognostic risk-scoring model for AML based on m7G-associated gene clustering Open
Background Acute myeloid leukemia (AML) patients still suffer from poor 5-year survival and relapse after remission. A better prognostic assessment tool is urgently needed. New evidence demonstrates that 7-methylguanosine (m7G) methylation…
View article: Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
Table S6
View article: Supplementary Data from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Supplementary Data from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
Supplementary_Figures
View article: Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
Table S4
View article: Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
Table S4
View article: Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
Table S1
View article: Data from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Data from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
N6-methyladenosine (m6A), the most abundant modification in mRNAs, has been defined as a crucial modulator in the progression of acute myelogenous leukemia (AML). Identification of the key regulators of m6A modifications in AML could provi…
View article: Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
Table S6
View article: Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
Table S5
View article: Supplementary Data from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Supplementary Data from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
Supplementary_Figures
View article: Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
Table S1
View article: Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
Table S2
View article: Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
Table S3
View article: Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
Table S2
View article: Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
Table S3
View article: Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
Table S5
View article: Data from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
Data from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
N6-methyladenosine (m6A), the most abundant modification in mRNAs, has been defined as a crucial modulator in the progression of acute myelogenous leukemia (AML). Identification of the key regulators of m6A modifications in AML could provi…
View article: The RNA m6A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
The RNA m6A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression Open
N6-methyladenosine (m6A), the most abundant modification in mRNAs, has been defined as a crucial modulator in the progression of acute myelogenous leukemia (AML). Identification of the key regulators of m6A modifications in AML could provi…
View article: The RNA m<sup>6</sup>A reader YTHDF1 promotes hematopoietic malignancy by maintaining oncogenic translation
The RNA m<sup>6</sup>A reader YTHDF1 promotes hematopoietic malignancy by maintaining oncogenic translation Open
N6-methyladenosine (m 6 A), the most abundant modification in mRNAs, has been defined as a crucial modulator in the progression of acute myeloid leukemia (AML), while the detailed mechanism remains elusive. Here we report that YTHDF1, an m…
View article: Yunnan Baiyao reduces hospital-acquired pressure ulcers via suppressing virulence gene expression and biofilm formation of <i>Staphylococcus aureus</i>
Yunnan Baiyao reduces hospital-acquired pressure ulcers via suppressing virulence gene expression and biofilm formation of <i>Staphylococcus aureus</i> Open
Yunnan Baiyao (YB) as a kind of famous Chinese herbal medicine, possessed hemostatic, invigorating the circulation of blood, and anti-inflammatory effects. Identifying strategies to protect patients at risk for hospital-acquired pressure u…